Sio Capital Management, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Sio Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $3.41 Million - $4.91 Million	-36,632 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $6.41 Million - $10.7 Million	-86,021 Reduced 70.13%	36,632 $4.22 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $2.05 Million - $2.54 Million	-28,900 Reduced 19.07%	122,653 $9.86 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $4.77 Million - $6.72 Million	72,400 Added 91.47%	151,553 $11 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $5.49 Million - $7.05 Million	-75,484 Reduced 48.81%	79,153 $7.4 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $3.16 Million - $4.46 Million	50,461 Added 48.44%	154,637 $11.3 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $6.51 Million - $9.12 Million	74,341 Added 249.17%	104,176 $9.12 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $2.63 Million - $3.22 Million	29,835 New	29,835 $2.94 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $2.32 Million - $2.83 Million	-20,225 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $1.47 Million - $2.39 Million	20,225	20,225 $2.38 Million

650

109M

1.28M

1.23M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.